Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation

Simple item page
dc.contributor.authorAlexander, JH
dc.contributor.authorSparapani, RA
dc.contributor.authorMahaffey, KW
dc.contributor.authorDeckers, JW
dc.contributor.authorNewby, LK
dc.contributor.authorOhman, EM
dc.contributor.authorCorbalán, R
dc.contributor.authorChierchia, SL
dc.contributor.authorBoland, JB
dc.contributor.authorSimoons, ML
dc.contributor.authorCaliff, RM
dc.contributor.authorTopol, EJ
dc.contributor.authorHarrington, RA
dc.date.accessioned2025-01-21T01:31:37Z
dc.date.available2025-01-21T01:31:37Z
dc.date.issued2000
dc.description.abstractContext Controversy surrounds the diagnostic and prognostic importance of slightly elevated cardiac markers in patients with acute coronary syndromes without ST-segment elevation.
dc.description.abstractObjectives To investigate the relationship between peak creatine kinase (CK)-MB level and outcome and to determine whether a threshold CK-MB level exists below which risk is not increased.
dc.description.abstractDesign and Setting Retrospective observational analysis of data from the international Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, conducted from November 1995 to January 1997,
dc.description.abstractPatients A total of 8250 patients with acute coronary sydromes without ST-segment elevation who had at least 1 CK-MB sample collected during their index hospitalization.
dc.description.abstractMain Outcome Measure Mortality at 30 days and 6 months, was assessed by category of index-hospitalization peak CK-MB level (0-1, >1-2, >2-3, >3-5, >5-10, or >10 times the upper limit of normal). Multivariable logistic regression was used to determine the independent prognostic significance of peak CK-MB level after adjustment for baseline predictors of 30-day and 6-month mortality.
dc.description.abstractResults Mortality at 30 days and 6 months increased from 1.8% and 4.0%, respectively, in patients with normal peak CK-MB levels, to 3.3% and 6.2% at peak CK-MB levels 1 to 2 times normal, to 5.1% and 7.5% at peak CK-MB levels 3 to 5 times normal, and to 8.3% and 11.0% at peak CK-MB levels greater than 10 times normal. Log-transformed peak CK-MB levels were predictive of adjusted 30-day and 6-month mortality (P<.001 for both).
dc.description.abstractConclusions Our data show that elevation of CK-MB level is strongly related to mortality in patients with acute coronary syndromes without ST-segment elevation, and that the increased risk begins with CK-MB levels just above normal. in the appropriate clinical context, even minor CK-MB elevations should be considered indicative of myocardial infarction.
dc.fuente.origenWOS
dc.identifier.issn0098-7484
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/97106
dc.identifier.wosidWOS:000084732400026
dc.issue.numero3
dc.language.isoen
dc.pagina.final353
dc.pagina.inicio347
dc.revistaJama-journal of the american medical association
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAssociation between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation
dc.typeartículo
dc.volumen283
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas